公开(公告)号：US20170044252A1

公开(公告)日：2017-02-16

申请号：US15337512

申请日：2016-10-28

Applicant: Janssen Biotech, Inc.

Inventor： Jacqueline Benson ,  Mark Cunningham ,  Cynthia Duchala ,  Jill Giles-Komar ,  Jinquan Luo ,  Michael Rycyzyn ,  Raymond Sweet

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K39/3955 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55527 ,  A61K2039/55544 ,  C07K16/244 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/55 ,  G01N33/6869 ,  G01N2333/54 ,  Y02A50/386 ,  Y02A50/401 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/55 ,  Y02A50/57 ,  Y02A50/58

Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract translation: 抗IL-23抗体，包括编码至少一种抗IL-23抗体，载体，宿主细胞，转基因动物或植物的分离的核酸及其制备和使用的方法具有诊断和/或治疗组合物中的应用 ，方法和设备。

公开(公告)号：US20160347840A1

公开(公告)日：2016-12-01

申请号：US15148371

申请日：2016-05-06

Applicant: Janssen Biotech, Inc.

Inventor： Glenn Anderson ,  Rosa Cardoso ,  Michael Diem ,  Francois Gaudet ,  Shalom Goldberg ,  Benjamin Harman ,  Linus Hyun ,  Steven Jacobs ,  Donna Klein ,  Yingzhe Li ,  Jinquan Luo ,  Ronan McDaid ,  Jill Mooney ,  Jennifer Nemeth-Seay ,  Karyn O'Neil ,  Steven Pomerantz ,  Galla Chandra Rao ,  Tracy Spinka-Doms ,  Alexey Teplyakov ,  Leopoldo Luistro ,  Sheng-Jiun Wu

IPC: C07K16/28 ,  C07K14/78 ,  A61K45/06 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6869 ,  A61K49/0045 ,  A61K49/0058 ,  A61K2039/505 ,  C07K14/78 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  C12Y304/17021

Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Abstract translation: 本文提供了分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段，其中FN3结构域特异性结合人前列腺特异性膜抗原（PSMA）和第二抗原结合位点免疫特异性结合CD3。 还描述了能够编码所提供的融合蛋白的融合蛋白和相关多核苷酸，以及表达所提供的融合蛋白的细胞。 此外，描述了使用所提供的分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段的方法。

公开(公告)号：US09505837B2

公开(公告)日：2016-11-29

申请号：US14812375

申请日：2015-07-29

Applicant: Janssen Biotech, Inc.

Inventor： Jacqueline Benson ,  Mark Cunningham ,  Cynthia Duchala ,  Jill M. Giles-Komar ,  Jinquan Luo ,  Michael A. Rycyzyn ,  Raymond Sweet

IPC: C07K16/24 ,  G01N33/68 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55527 ,  A61K2039/55544 ,  C07K16/244 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/55 ,  G01N33/6869 ,  G01N2333/54 ,  Y02A50/386 ,  Y02A50/401 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/55 ,  Y02A50/57 ,  Y02A50/58

Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

公开(公告)号：US20160326232A1

公开(公告)日：2016-11-10

申请号：US15148312

申请日：2016-05-06

Applicant: Janssen Biotech, Inc.

Inventor： Cardosa Rosa ,  Michael Diem ,  Shalom Goldberg ,  Linus Hyun ,  Steven Jacobs ,  Donna Klein ,  Karyn O'Neil ,  Tracy Spinka-Doms

IPC: C07K14/78 ,  G01N33/573 ,  A61K51/08

CPC classification number: C07K14/78 ,  A61K38/00 ,  A61K51/08 ,  G01N33/57434 ,  G01N2333/705

Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Abstract translation: PSMA结合FN3结构域，它们的缀合物，编码分子的分离的核苷酸，载体，宿主细胞及其制备方法可用于治疗分子的产生以及疾病和病症的治疗和诊断。

公开(公告)号：US09481731B2

公开(公告)日：2016-11-01

申请号：US13751718

申请日：2013-01-28

Applicant: Janssen Biotech, Inc.

Inventor： Mark Cunningham ,  Yiqing Feng ,  Katharine Heeringa ,  Jinquan Luo ,  Robert Rauchenberger ,  Mark Rutz ,  Lani San Mateo ,  Robert Sarisky ,  Vedrana Stojanovic-Susulic ,  Raymond Sweet ,  Fang Teng ,  Alexey Teplyakov ,  Sheng-Jiun Wu

IPC: C07K16/18 ,  C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K14/435 ,  C07K14/705

CPC classification number: C07K16/2896 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/10 ,  C12N5/12 ,  C12N15/117 ,  C12N15/63 ,  C12N2310/17 ,  A61K39/00 ,  A61K2300/00

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

公开(公告)号：US09458430B2

公开(公告)日：2016-10-04

申请号：US14882661

申请日：2015-10-14

Applicant: Janssen Biotech, Inc.

Inventor： Alireza Rezania

IPC: C12N5/02 ,  C12N5/00 ,  C12N5/071

CPC classification number: C12N5/0678 ,  C12N2501/115 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02

Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method utilizing a CYP26A inhibitor to produce a population of pancreatic endocrine precursor cells.

公开(公告)号：US20160222104A1

公开(公告)日：2016-08-04

申请号：US15132851

申请日：2016-04-19

Applicant: Janssen Biotech, Inc.

Inventor： Yan Chen ,  Debra Gardner ,  David M. Knight ,  Michael W. Lark ,  Bailin Liang ,  David M. Marquis ,  David J. Shealy ,  Eric Michael Smith ,  Xiao-yu R. Song ,  Vedrana Stojanovic-Susulic ,  Raymond W. Sweet ,  Susan Tam ,  Alain P. Vasserot ,  Sheng-Jiun Wu ,  Jing Yang

IPC: C07K16/24

CPC classification number: C07K16/248 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2316/96 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract translation: 包含具有液体制剂的抗IL-6抗体的笔式注射器装置在诊断和/或治疗组合物，方法和装置中具有应用。

公开(公告)号：US09388387B2

公开(公告)日：2016-07-12

申请号：US14661647

申请日：2015-03-18

Applicant: Janssen Biotech, Inc.

Inventor： Alireza Rezania

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/70 ,  C12N2501/998 ,  C12N2506/02

Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides a method to increase the expression of markers associated with the pancreatic endocrine lineage.

公开(公告)号：US09388386B2

公开(公告)日：2016-07-12

申请号：US13708369

申请日：2012-12-07

Applicant: Janssen Biotech, Inc.

Inventor： Alireza Rezania

IPC: C12N5/00 ,  C12N5/02 ,  C12N5/071

CPC classification number: C12N5/0676 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2501/117 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/19 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2506/02

Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.

Abstract translation: 本发明提供促进多能干细胞分化的方法。 特别地，本发明提供了产生细胞群的方法，其中群体中大于10％的细胞表达单个激素胰腺β细胞特征的标志物。

公开(公告)号：US20160194405A1

公开(公告)日：2016-07-07

申请号：US14992519

申请日：2016-01-11

Applicant: Janssen Biotech, Inc.

Inventor： G. Mark Anderson ,  Bernard Scallon ,  Michael Naso ,  Ann Cai ,  Cam Holland

IPC: C07K16/36 ,  A61K31/4164 ,  A61K51/00 ,  A61K47/48 ,  A61K9/00 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/36 ,  A61K9/0019 ,  A61K31/4164 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/00 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.